Core Insights - Coeur Mining, Inc. (NYSE:CDE) is identified as an undervalued growth stock, recently upgraded to a Buy by Cantor Fitzgerald, with a revised price target of $20 from $24 [1][2] Financial Performance - For 2025, Coeur Mining reported revenue of $2.1 billion and net income from continuing operations of $493 million [2] - The company anticipates gold production of 390,000-460,000 ounces and silver production of 18.2-21.3 million ounces for 2026, projecting a combined EBITDA of $3 billion and free cash flow of $2 billion [2] Strategic Developments - Coeur Mining completed the acquisition of New Gold Inc., positioning itself as a leading North American precious metals producer [3] - Post-acquisition, the company expects to produce between 680,000 and 815,000 ounces of gold, 18.7 to 21.9 million ounces of silver, and 50 to 65 million pounds of copper [3] Company Overview - Coeur Mining is a well-diversified precious metals producer focused on gold and silver assets in North America, operating key mines such as the Rochester mine in Nevada and the Palmarejo complex in Mexico [4]

Core Points - Valeo filed its 2025 Universal Registration Document with the French financial markets authority on March 31, 2026, under number D.26-0184 [2] - The document includes the Integrated Report, Annual Financial Report, Corporate Governance Report, Sustainability Report, and details on the Company's share buyback program [2] - The 2025 Universal Registration Document is publicly available on Valeo's website and the AMF website [3] Company Overview - Valeo is a leading global technology company focused on innovative solutions for automotive and technology partners [4] - The company is structured into POWER, BRAIN, and LIGHT Divisions, along with Valeo Service for aftermarket and new mobility solutions [4] - Valeo aims to enhance mobility by making it safer, more sustainable, and affordable, contributing to the development of the electrified, safer, and software-defined Car of Tomorrow [5] Financial and Operational Highlights - Valeo reported sales of €20.9 billion in 2025, employing 100,000 people across 29 countries [6] - The company operates 149 production plants, 59 R&D centers, and 19 distribution platforms as of February 26, 2026 [6]

Group 1: Fund Performance - Parnassus Mid Cap Fund outperformed the Russell Midcap Index in Q4 2025, returning 1.17% (net of fees) compared to the index's 0.16% [1] - Year-to-date (YTD), the Fund achieved a return of 12.85% (net of fees), exceeding the index's 10.60% return [1] - The Fund's performance was bolstered by investments in the Information Technology sector and Utilities [1] Group 2: Market Outlook - The Fund is optimistic about mid-cap stocks driving market growth in 2026, especially if economic expansion continues beyond artificial intelligence [1] - In the event of a market decline, the Fund believes its portfolio of financially solid companies will provide downside protection [1] Group 3: Brookfield Renewable Corporation - Brookfield Renewable Corporation (NYSE:BEPC) was highlighted as a leading contributor to the Fund's performance, with a market capitalization of $7.03 billion [2] - The stock experienced a one-month return of -6.09% but gained 36.29% over the past 52 weeks [2] - The company benefited from an $80 billion strategic partnership with the U.S. Department of Commerce to build nuclear reactors for data centers [3] Group 4: Hedge Fund Interest - Brookfield Renewable Corporation (NYSE:BEPC) was held by 25 hedge fund portfolios at the end of Q4 2025, a decrease from 27 in the previous quarter [4] - While the potential of Brookfield Renewable Corporation is acknowledged, certain AI stocks are considered to offer greater upside potential and less downside risk [4]

Core Insights - The U.S. housing market is showing signs of normalization with a decrease in the 30-year fixed-rate mortgage to 5.98% as of February 26, 2026, after being above 6% for over a year [1] - However, geopolitical tensions and tariffs have led to a rise in mortgage rates to 6.38% by March 26, 2026, impacting homebuyer affordability and potentially slowing demand [2] - Federal Reserve Chair Jerome Powell expressed optimism about inflation responding less to oil price hikes and tariffs, indicating the Fed's interest rate benchmark is in a good position for observing future developments [3] Housing Market Dynamics - Despite elevated mortgage rates and inflation concerns, the homebuilding industry has a positive mid- to long-term outlook due to strong structural fundamentals [5] - A persistent housing supply shortage is stabilizing home prices, while homebuilders are offering incentives like mortgage rate buydowns to maintain sales momentum [6] - Homebuilders are in a stronger financial position compared to previous cycles, with better inventory management and healthier balance sheets, allowing them to navigate short-term volatility [6] Inflation and Economic Outlook - Jerome Powell's statements suggest inflation could stabilize near 2% without tariffs, indicating a critical inflection point for the housing market amid easing inflation expectations and high mortgage rates [7] - The trajectory of inflation will be crucial in determining whether the housing market recovers or remains stagnant [8] Earnings Estimates for Homebuilders - Beazer Homes USA (BZH) has seen a decline in earnings estimates for fiscal 2026 by 57.1%, but a significant growth of 283.8% is expected for fiscal 2027 [11] - Century Communities (CCS) has experienced a 22.5% decline in earnings estimates for 2026, while estimates for 2027 remain stable with a projected growth of 63.2% [12] - D.R. Horton (DHI) has a 9.5% decline in earnings estimates for fiscal 2026, but a growth of 16.1% is anticipated for fiscal 2027 [14]

Core Insights - NIO Inc. has launched its first showroom in the Americas, specifically a NIO House in San José, Costa Rica, in collaboration with Horizontes Cielo Azul, the largest electric vehicle distributor in the country [1][12] Expansion Strategy - This launch marks NIO's entry into the Western Hemisphere, with Costa Rica being the first overseas market to introduce all three of its brands—NIO, ONVO, and FIREFLY—simultaneously [2][12] - The company has shifted from a direct-sales model to a distributor-led approach, as evidenced by its partnership in Costa Rica [5][12] Product Offering - Customers can explore and purchase various models, including the ET5 Touring, EL6, EL8, ONVO L60, and FIREFLY vehicles, with the EL6 and EL8 corresponding to the ES6 and ES8 models sold in China [3][12] - The ONVO L90 large SUV is expected to begin pre-sales on April 16, 2026 [3] Market Context - Costa Rica has a significant market for electric vehicles, with a 15.4% share of pure battery electric vehicle sales in 2024, the highest in the Americas for three consecutive years [6] - Chinese brands account for approximately 70% of EVs in circulation in Costa Rica [6] Future Goals - By the end of 2025, NIO aims to expand to 20 markets worldwide, with a target of reaching 40 countries and regions by the end of 2026, positioning FIREFLY as the lead brand for global expansion [7][12] Challenges - The company faces near-term challenges in Costa Rica, including a reduction in tax benefits and the introduction of a 7.5% consumption tax, which has increased EV prices by roughly 10% [8] - NIO's premium vehicle pricing may affect its sales volume, making brand positioning a critical aspect of its strategy in the region [8] Performance Metrics - NIO delivered 326,028 vehicles across its three brands in 2025, representing a 46.9% year-over-year increase, and achieved its first quarterly net profit in Q4 2025 [9] - For Q1 2026, the company expects deliveries to be between 80,000 and 83,000 units [9]

Core Insights - Zacks Premium offers various tools to help investors make informed decisions and enhance their confidence in stock market investments [1] Zacks Style Scores - The Zacks Style Scores are indicators designed to assist investors in selecting stocks with the highest potential to outperform the market within a 30-day timeframe [2] - Stocks are rated from A to F based on their value, growth, and momentum characteristics, with A being the highest score [2] Value Score - The Value Style Score focuses on identifying undervalued stocks by analyzing financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Style Score evaluates a company's future prospects and financial health by examining projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Style Score identifies optimal times to invest based on price trends and earnings estimate changes, emphasizing the importance of market trends [5] VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores to highlight stocks with the best overall potential, making it a valuable tool alongside the Zacks Rank [6] Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically delivered an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize potential returns [10] - Stocks with lower ranks, even if they have high Style Scores, may still face downward price pressure due to negative earnings outlooks [11] Company Spotlight: Flowserve Corporation - Flowserve Corporation, established in 1912 and based in Irving, TX, is a leading manufacturer of flow control systems [12] - Flowserve holds a Zacks Rank of 2 (Buy) and has a VGM Score of A, indicating strong growth potential [12] - The company is projected to achieve a year-over-year earnings growth of 12.9% for the current fiscal year, supported by upward revisions in earnings estimates [13]

Core Viewpoint - The biotech sector is experiencing increased attention from notable financial figures, indicating a potential market shift reminiscent of previous significant market events [1]. Group 1: Market Analysis - Jamie Dimon of JPMorgan Chase & Co. and Michael Burry, known for "The Big Short," have noted that current market conditions are increasingly similar to the lead-up to major financial events [1]. - Bret Jensen, a market analyst with over 13 years of experience, focuses on identifying high-potential biotech stocks, suggesting a bullish outlook for the sector [1]. Group 2: Investment Strategies - The Biotech Forum, led by Bret Jensen, offers a model portfolio consisting of 12-20 biotech stocks with high upside potential, along with live discussions and weekly updates [1]. - The forum provides a platform for investors to engage in discussions about specific covered call trades, indicating a proactive investment strategy within the biotech space [1].

Company Overview - Ross Stores Inc. operates as an off-price retailer of apparel and home accessories primarily in the United States, with stores under the Ross Dress for Less and dd's DISCOUNTS names [11] - The company's stores are mainly located in community and neighborhood shopping centers in heavily populated urban and suburban areas [11] Investment Ratings - Ross Stores has a Zacks Rank of 2 (Buy) and a VGM Score of B, indicating a favorable investment outlook [11] - The company is also considered a top pick for growth investors due to its strong growth metrics [12] Growth Potential - Ross Stores is forecasted to achieve year-over-year earnings growth of 10.1% for the current fiscal year [12] - Seven analysts have revised their earnings estimates upwards in the last 60 days for fiscal 2027, with the Zacks Consensus Estimate increasing by $0.16 to $7.28 per share [12] - The company boasts an average earnings surprise of +6.2%, further indicating its strong performance potential [12]

Core Viewpoint - Eli Lilly has agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, focusing on a new class of drugs for excessive daytime sleepiness and related neurological conditions [1][2]. Group 1: Acquisition Details - Lilly will pay $38 per share upfront, totaling $6.3 billion, which represents a 38% premium over Centessa's closing price prior to the announcement [3]. - An additional payment of up to $1.5 billion is contingent on the approval of Centessa's drugs by the U.S. FDA by specific deadlines [3]. - The transaction is expected to close in the third quarter, pending regulatory approval [4]. Group 2: Market Potential - The market for orexin agonists, which treat narcolepsy and idiopathic hypersomnia, could reach between $15 billion to $20 billion if approximately one quarter of patients seek treatment [4]. - Sales could increase further if these drugs are utilized for a broader range of conditions [4]. Group 3: Competitive Landscape - Centessa's orexin agonist will not be the first to market, as a rival drug from Takeda is currently under FDA review and may receive approval later this year [5]. - Analysts predict that Centessa's drug may not be approved until 2028, but mid-stage trial data suggests it could become the best in class [5]. Group 4: Company Background - Lilly has a strong history in neuroscience, with its antidepressant Prozac significantly boosting its position in the pharmaceutical industry since its approval in 1987 [6]. - Recently, Lilly introduced Kisunla for early-stage Alzheimer's disease and is planning further trials to assess its efficacy in preventing the disease [6]. - The company aims to leverage revenue from its successful obesity and diabetes drugs, Zepbound and Mounjaro, to fund additional acquisitions [7].

Most wedding gifts land somewhere between a home appliance and an envelope with cash. This one landed at $50,000—and still managed to stir up a fight. A financial boost that changed the timeline In a post on Reddit, a 55-year-old uncle laid out the situation plainly. He had retired comfortably after "getting really lucky with investments" and said he and his wife have "more than enough to live comfortably for the rest of our lives." His 24-year-old nephew, meanwhile, was juggling everything at once. Th ...